MARKET

GRFS

GRFS

Grifols S A
NASDAQ
10.37
+0.12
+1.17%
After Hours: 10.37 0 0.00% 16:01 12/08 EST
OPEN
10.31
PREV CLOSE
10.25
HIGH
10.41
LOW
10.31
VOLUME
2.18M
TURNOVER
0
52 WEEK HIGH
10.97
52 WEEK LOW
6.50
MARKET CAP
7.04B
P/E (TTM)
1205.81
1D
5D
1M
3M
1Y
5Y
Grifols Is Building Momentum
Grifols is in advanced negotiations to sell shanghai raas, which would eliminate short-term debt concerns. Argenx's failure removes competitive pressure on grifols' immunoglobulin franchise. Q3 results showed increased sales, improved ebitda margin, and higher plasma supply.
Seeking Alpha · 8h ago
Kepler Capital Keeps Their Buy Rating on Grifols SA (GRFS)
TipRanks · 3d ago
JP Morgan Maintains Neutral Rating for Grifols: Here's What You Need To Know
Jp morgan has maintained its neutral rating of grifols and raised its price target from $10.00 to $11.50. Shares of the company are trading up 0.62% over the last 24 hours. Grifols is a vertically integrated plasma derivative producer.
Benzinga · 3d ago
JP Morgan Maintains Neutral on Grifols, Raises Price Target to $10.5
Benzinga · 3d ago
Weekly Report: what happened at GRFS last week (1127-1201)?
Weekly Report · 4d ago
Kepler Capital Remains a Buy on Grifols SA (GRFS)
Kepler capital analyst pablo de renteria maintained a buy rating on grifols sa (grfs) with a price target of €17.50. The analyst consensus on the stock is a moderate buy. The company produces plasma derivatives and has a market cap of $8.65b.
TipRanks · 12/01 01:55
Grifols said to be in talks for a partial sale of Shanghai RAAS
Healthcare grifols said to be in talks for a partial sale of shanghai raas blood products co. Bloomberg says the spanish company is in discussions with state-owned china merchants group ltd. To divest a part of its minority ownership in shanghai raas. A deal could also change ownership at the company's diagnostics division.
Seeking Alpha · 11/29 13:21
Weekly Report: what happened at GRFS last week (1120-1124)?
Weekly Report · 11/27 09:27
More
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Webull offers Grifols SA - ADR stock information, including NASDAQ: GRFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRFS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRFS stock methods without spending real money on the virtual paper trading platform.